title: Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
abstract: OBJECTIVE
  To study the protective effects of valsartan (Val) and benazepril, (Ben) combined with atorvastatin (Ato), on cardiorenal syndrome (CRS) in rats.
  
  
  METHODS
  After establishing cardiorenal syndrome model, the rats were randomly divided into control, Ato, Ben+Ato and Val+Ato groups, which were treated with corresponding drugs. Before and 4 weeks after treatment, the serum creatinine (Scr), blood urea nitrogen (BUN), type-B natriuretic peptide (BNP), aldosterone (ALD), angiotensin (Ang) II, C-reactive protein (CRP), blood lipid and urine protein were determined. The left ventricular systolic pressure (LVSP), left ventricular diastolic pressure (LVDP), left ventricular end-diastolic pressure (LVEDP) as well as maximum rising and falling rates of left ventricular pressure (±dp/dtmax) were detected. The heart weight index was also determined.
  
  
  RESULTS
  6, 3, 1 and 2 rats control, Ato, Ben+Ato and Val+Ato groups died, respectively. Compared with control group, the serum Cr, BUN, BNP, ALD, CRP and urinary protein levels in treatment groups significantly decreased, and the blood lipid level, LVDP, LVEDP and heart weight index significantly decreased, with increased LVSP. No statistically significant difference was observed among treatment groups.
  
  
  CONCLUSIONS
  Valsartan and benazepril, combined with atorvastatin, can have significant protective effects on cardiorenal functions of rats with CRS, with no significant difference between these two drugs.
authors: Department of Cardiology, Affiliated Puai Hospital, Tongji Medical College, Wuhan, Hubei Province, China. dingfengpeng@126.com.
authors: S-Y
authors: SY
authors: Tang
authors: D-F
authors: DF
authors: Peng
authors: Y-J
authors: YJ
authors: Hu
authors: J
authors: J
authors: Chen
mesh_terms: D000804:Angiotensin II / Q000097:blood; D000818:Animals; D000069059:Atorvastatin; D001552:Benzazepines / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000378:metabolism; D059347:Cardio-Renal Syndrome / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D016022:Case-Control Studies; D004357:Drug Synergism; D006538:Heptanoic Acids / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011507:Proteinuria / Q000652:urine; D011758:Pyrroles / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
chemical_list: D001552:Benzazepines; D006538:Heptanoic Acids; D008055:Lipids; D011758:Pyrroles; D013777:Tetrazoles; D000804:Angiotensin II; D020097:Natriuretic Peptide, Brain; D000068756:Valsartan; D002097:C-Reactive Protein; D000069059:Atorvastatin; D014633:Valine; C044946:benazepril